Literature DB >> 5531904

Phenolic acid concentrations in the lumbar cerebrospinal fluid of Parkinsonian patients treated with L-dopa.

I A Pullar, J M Weddell, R Ahmed, F J Gillingham.   

Abstract

The acid metabolites of dopamine and 5-hydroxytryptamine were estimated in the lumbar cerebrospinal fluid (CSF) of Parkinsonian patients both before and during treatment with l-dopa, the amino acid precursor of dopamine. An attempt was made to relate clinical improvement to the biochemical results. The dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, showed increases related to the dose of l-dopa, the increase in homovanillic acid concentration being proportionately greater than that of 3,4-dihydroxyphenylacetic acid. The concentration of the 5-hydroxytryptamine metabolite, 5-hydroxyindol-3ylacetic acid, was unaltered by the drug. Clinical improvement, which in the early stages was evident particularly in the bradykinesia, was found to occur at doses of l-dopa greater than 1·5 g/day. Effective doses of l-dopa gave rise to concentrations of dopamine metabolites in the CSF which were greater than normal. Possible implications of these findings are discussed.

Entities:  

Mesh:

Year:  1970        PMID: 5531904      PMCID: PMC493603          DOI: 10.1136/jnnp.33.6.851

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  IN-VITRO DECARBOXYLATION OF NEW PHENYLALANINE DERIVATIVES.

Authors:  R FERRINI; A GLAESSER
Journal:  Biochem Pharmacol       Date:  1964-05       Impact factor: 5.858

2.  On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.

Authors:  N E ANDEN; B E ROOS; B WERDINIUS
Journal:  Life Sci (1962)       Date:  1963-07

3.  The surgical treatment of parkinsonism.

Authors:  F J GILLINGHAM; W S WATSON; A A DONALDSON; J A NAUGHTON
Journal:  Br Med J       Date:  1960-11-12

4.  Cholinergic-anticholinergic antagonism in parkinsonism.

Authors:  R C Duvoisin
Journal:  Arch Neurol       Date:  1967-08

5.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

6.  Homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in serial samples of cerebrospinal fluid from the lateral ventricle of the dog.

Authors:  G W Ashcroft; T B Crawford; R C Dow; H C Guldberg
Journal:  Br J Pharmacol Chemother       Date:  1968-07

7.  Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid.

Authors:  H C Guldberg; C M Yates
Journal:  Br J Pharmacol Chemother       Date:  1968-07

8.  Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.

Authors:  A Pletscher; G Bartholini; R Tissot
Journal:  Brain Res       Date:  1967-02       Impact factor: 3.252

9.  The metabolism of orally administered L-Dopa in Parkinsonism.

Authors:  D B Calne; F Karoum; C R Ruthven; M Sandler
Journal:  Br J Pharmacol       Date:  1969-09       Impact factor: 8.739

10.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

View more
  12 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

3.  Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF.

Authors:  O Yazici; A Hizal; L Eroğlu; A Baslo; J Yazici
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

4.  Amine metabolites in the cerbrospinal fluid in Huntington's chorea.

Authors:  G Curzon; J Gumpert; D Sharpe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-08       Impact factor: 10.154

Review 5.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Monoamine metabolites in cerebrospinal fluid in multiple sclerosis.

Authors:  D Davidson; I A Pullar; C Mawdsley; N Kinloch; C M Yates
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-08       Impact factor: 10.154

7.  The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

Authors:  S Bergmann; G Curzon; J Friedel; R B Godwin-Austen; C D Marsden; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

8.  CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

Authors:  D L Davidson; C M Yates; C Mawdsley; I A Pullar; H Wilson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-12       Impact factor: 10.154

9.  Dopamine and serotonin metabolism in hepatic encephalopathy.

Authors:  A J Knell; A R Davidson; R Williams; B D Kantamaneni; G Curzon
Journal:  Br Med J       Date:  1974-03-23

10.  Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis.

Authors:  L E Claveria; G Curzon; M J Harrison; B D Kantamaneni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.